ecogacrinnews2

August 16, 2022

NCI-MATCH precision medicine trial leads to FDA drug approval for BRAF V600E-mutated tumors

Dabrafenib/trametinib is the first and only BRAF/MEK inhibitor combination to be approved with a tumor-agnostic indication for solid tumors carrying the BRAF V600E mutation
August 16, 2022

Trial Spotlight: Neha Vapiwala on the EA8191/INDICATE Study for Prostate Cancer

This phase III study is using PET/CT imaging to guide treatment for patients with post-prostatectomy biochemical recurrence
August 16, 2022

News in Brief, August 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
April 15, 2022

Trial Spotlight: Nadine Tung on the EA1181/CompassHER2 pCR Trial for HER2-Positive Breast Cancer

This study aims to determine if it is safe to omit adjuvant chemotherapy after surgery for patients with pathologic complete response (pCR) after 12 weeks of pre-operative treatment
April 15, 2022

News in Brief, April 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
February 24, 2022

From the Co-Chairs, February 2022

Reflections on the 50th Anniversary of the National Cancer Act of 1971
February 24, 2022

Now Enrolling: EA2205 for a Rare Form of Liver Cancer

ECOG-ACRIN is leading the first randomized trial evaluating treatment strategies for patients with combined hepatocellular carcinoma-cholangiocarcinoma
February 24, 2022

Edith Mitchell Reflects on Equity Initiatives at ECOG-ACRIN

On the occasion of Black History Month, ECOG-ACRIN speaks with Edith Mitchell, MD about health equity and diversity initiatives within the Group
February 24, 2022

ECOG-ACRIN Sarcoma Working Group Builds Steam in Second Year

Kenneth Cardona, MD, FACS, of the Winship Cancer Institute at Emory University, discusses the Sarcoma Working Group’s progress to date and outlines future plans
February 24, 2022

Trial Spotlight: Nataliya Uboha on the EA2183 Trial for Esophageal and Gastric Adenocarcinoma

This randomized phase III trial explores the addition of radiotherapy to the usual treatment (chemotherapy) in patients with esophagus and stomach cancer with limited spread
February 24, 2022

News in Brief, February 2022

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
January 26, 2022

Come Again? Communicating Clearly About Risk of Recurrence After Early-Stage Breast Cancer

Mary Lou Smith and colleagues at the Research Advocacy Network recently explored how well patients with early-stage breast cancer understand risk of recurrence